Investor Invus Public Equities, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Invus Public Equities, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2021-02-16 13G/A SQZ / SQZ Biotechnologies Co 1,606,308 1,606,308
2021-02-16 13G/A SQZ / SQZ Biotechnologies Co 1,606,308 1,606,308
2020-11-13 13G SQZ / SQZ Biotechnologies Co 1,606,308
2019-02-12 13G/A PRQR / ProQR Therapeutics N.V. 1,900,000 1,400,000
2018-02-09 13G PRQR / ProQR Therapeutics N.V. 1,500,000 1,900,000
2017-07-06 13G PRQR / ProQR Therapeutics N.V. 1,500,000
2014-02-14 13G/A AUXL / Auxilium Pharmaceuticals Inc 2,700,000
2014-02-14 13G/A FURX / Furiex Pharmaceuticals, Inc. 870,842
2013-08-27 13G SPHS / Sophiris Bio Inc 1,000,000
2013-02-19 13G/A FURX / Furiex Pharmaceuticals, Inc. 1,003,400
2013-01-31 13G/A AUXL / Auxilium Pharmaceuticals Inc 2,637,200
2013-01-31 13G/A FURX / Furiex Pharmaceuticals, Inc. 928,400
2012-04-10 13G/A AUXL / Auxilium Pharmaceuticals Inc 2,649,800
2012-04-10 13G/A FURX / Furiex Pharmaceuticals, Inc. 695,000
2012-02-14 13G/A AUXL / Auxilium Pharmaceuticals Inc 2,949,800
2012-02-14 13G/A FURX / Furiex Pharmaceuticals, Inc. 695,000
2012-02-13 13G/A ACOR / Acorda Therapeutics, Inc. 1,700,000
2012-02-13 13G/A AGEN / Agenus Inc. 4,546,079
2012-02-13 13G/A VNDA / Vanda Pharmaceuticals Inc. 1,830,000
2012-02-13 13G/A US0153511094 / Alexion Pharmaceuticals, Inc. 1,500,000